Month: November 2022

On April 28, 2022, Berlin, Michael; Crew, Andrew; Dong, Hanqing; Hornberger, Keith; Snyder, Lawrence; Wang, Jing; Zimmermann, Kurt published a patent.Quality Control of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate The title of the patent was Preparation of bifunctional compounds and methods for the targeted degradation of androgen receptor protein. And the patent contained the following:

Bifunctional compounds e.g. I, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Example I was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their androgen receptor modulatory activity (some data given). The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).Quality Control of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate

The Article related to bifunctional preparation targeted degradation androgen receptor modulator anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 1, 2022, Zhang, Chen; Liao, Yuting; He, Ping; Chen, Xiaogang; Xuan, Zhaoli; Ye, Fei; Tang, Pingming; Wan, Songlin; Li, Yao; Ni, Jia; Yan, Pangke published a patent.COA of Formula: C15H29N3O2 The title of the patent was Preparation of BTK inhibitor cyclic derivative and its pharmaceutical application in treatment of BTK-related diseases. And the patent contained the following:

The present invention relates to preparation of BTK inhibitor cyclic derivative and its pharmaceutical application in treatment of BTK-related diseases. In particular, the BTK inhibitor ring derivative B-L-K (wherein, L = -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-; Ak1 – Ak5 = CH2, O, -NRb0-, C=O, C=C or bond; Cy1 – Cy4 = optionally substituted 3-12 membered heterocycle, optionally substituted 3-12 membered cycloalkyl, optionally substituted 6-10 membered aryl, or bond; B = B1-W1-B2-B3-B4- or I, when B = B1-W1-B2-B3-B4-, Cy1, Cy2, Cy3, and Cy4 cannot be bonds at the same time; when B = B1-W1-B2-B3-B4-, and Ak1, Ak2, Ak3, Ak4 or Ak5 are not bonds, they cannot be directly connected to each other). Further, (B1 and B2 = optionally substituted 6-membered heteroaromatic ring or phenyl; W1 = -O-, -S-, -NH-, -NHCO- or -CONH-; B3 = optionally substituted heterocyclic ring; B4 = optionally substituted 4-7-membered monocycloalkyl, optionally substituted 6-12-membered spirocycloalkyl, optionally substituted 5-10-membered cycloalkyl derivative etc.; B5 or B6 = optionally substituted Ph or 5-6-membered heteroaryl; Rb6 = H, C1-4 alkyl, halogen-substituted C1-4 alkyl or hydroxy-substituted C1-4 alkyl; Rb7 and Rb8 = H, F, Cl, Br, I, OH, NH2, CN, CF3, -C(=O)NH2 etc.; m = 0, 1 or 2; K = heterocyclic group, cycloalkyl carbonyl-group, aralkyl carbonyl-group etc.) or stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof were prepared The inventive BTK inhibitor cyclic derivatives are useful for treating BTK-related diseases such as tumors or autoimmune system diseases. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).COA of Formula: C15H29N3O2

The Article related to azaheterocyclic compound preparation btk inhibitor antitumor autoimmune disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C15H29N3O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2020, G. Lindstroem, H. Jonathan; Friedman, Ran published an article.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. And the article contained the following:

Abstract: Background: Chronic myeloid leukemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib-dasatinib, imatinib-asciminib and dasatinib-asciminib combinations and calculated combination index graphs for each case. Moreover, using the median-effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition. Simulations revealed that asciminib may allow for dose reductions, and its complementary resistance profile could reduce the risk of mutation based resistance. Axitinib, however, had only a minor effect on T315I growth advantage. Conclusions: Given how asciminib combinations were synergistic in vitro, our modeling suggests that drug combinations involving asciminib should allow for lower total drug doses, and may result in a reduced spectrum of observed resistance mutations. On the other hand, a combination involving axitinib was not shown to be useful in countering drug resistance. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to axitinib asciminib antitumor tyrosine kinase inhibitor chronic myeloid leukemia, allosteric inhibitor, drug combination, targeted therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Claudiani, Simone; Janssen, Jeroen J. W. M.; Byrne, Jenny; Smith, Graeme; Blijlevens, Nicole; Raghavan, Manoj; Smith, Matthew; Clark, Richard E.; Mclain-Smith, Susan; Carter, Angela M.; Milojkovic, Dragana; Apperley, Jane F. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. And the article contained the following:

To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 mo. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major mol. response rates in CP patients were 67% and 55%, resp. After a median follow-up of 21.5 mo, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, resp. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%). Bosutinib used in routine clin. practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib anticancer agent chronic myeloid leukemia, bosutinib, chronic myeloid leukemia, retrospective studies, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Zhang, Lishun; Yang, Zichao; Sang, Huiting; Jiang, Ying; Zhou, Mingfeng; Huang, Chuan; Huang, Chunhui; Wu, Xiaoyun; Zhang, Tingting; Zhang, Xingmei; Wan, Shanhe; Zhang, Jiajie published an article in 2021, the title of the article was Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.Recommanded Product: 380843-75-4 And the article contains the following content:

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention. Herein, a new series of imidazo[4,5-c]pyridin-2-one derivatives were designed and synthesized as SFK inhibitors. Compounds , , , exhibited potential Src and Fyn kinase inhibition in the submicromolar range, of which were next tested for their antiproliferative potency on four GBM cell lines. Compound showed effective activity against U87, U251, T98G, and U87-EGFRvIII GBM cell lines, comparable to that of lead compound PP2. Mol. dynamics (MDs) simulation revealed the possible binding patterns of the most active compound in ATP binding site of SFKs. ADME prediction suggested that accord with the criteria of CNS drugs. These results led us to identify a novel SFK inhibitor as candidate for GBM treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4

The Article related to dasatinib anticancer agent glioblastoma, glioblastoma, src family kinase, imidazo[4,5-c]pyridin-2-one, kinase inhibitor, molecular simulation, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2022, Nakajima, Rui; Matsuo, Takuji; Sumiyoshi, Ritsu; Saito, Sumiko; Yamamoto, Tadashi; Matsumoto, Kensuke; Akiyama, Nobu; Ooi, Jun; Ota, Yasunori; Shirafuji, Naoki; Tashiro, Haruko published an article.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib. And the article contained the following:

FIrst report of an extramedullary blast crisis in the lymph nodes of a chronic myeloid leukemia (CML) patient on bosutinib. A 78-yr-old man was diagnosed with chronic phase (CP) CML in March 2015 and was treated with dasatinib 100 mg once daily as a first-line therapy. An excisional lymph node biopsy revealed the proliferation of blast cells with a starry-sky appearance. Bone marrow anal. did not indicate an increase in abnormal cells, and FISH anal. showed an absence of BCR-ABL1 fusion genes. From these findings, the patient was diagnosed with extramedullary B-lymphoid blast crisis that occurred in CP CML while under MMR. This case demonstrates the need to be mindful of the possibility of extramedullary disease even in patients having achieved MMR following TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib antitumor chronic myeloid leukemia extramedullary blast crisis, cml, bosutinib, extramedullary, ponatinib, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Yue, Xiaomeng; Hincapie, Ana L.; Li, Yuxiang; Guo, Jeff J. published an article in 2022, the title of the article was Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.Computed Properties of 380843-75-4 And the article contains the following content:

To evaluate the cost-effectiveness of ponatinib compared with second-line TKIs in the treatment of adult patients with CML who failed, or were intolerant to, first-line TKIs. A Markov state transition model was conducted. Model transition, adverse-effect probabilities, utility data and medical costs were obtained from clin. trials and literature. Measurements included medications, follow-ups, adverse events, allogeneic stem cell transplantation and quality-adjusted life years (QALYs). Univariable and Bayesian multivariable probabilistic sensitivity analyses were conducted using Monte Carlo simulations. Dasatinib resulted in an ICER of $79,086/QALY compared to nilotinib. Ponatinib yielded an ICER of $176,278/QALY and $141,563/QALY compared to dasatinib and nilotinib, resp. Dasatinib was the optimal treatment at a $100,000/QALY threshold. The probability (36%-40%) for ponatinib or dasatinib optimal treatment was associated with thresholds of $160,000-$180,000/QALY. Dasatinib and ponatinib can be considered cost-effective options and provide clin. benefits compared to other second-line TKIs for CML in the US. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to ponatinib dasatinib anticancer agent economic evaluation chronic myeloid leukemia, treatment outcome, bosutinib, dasatinib, nilotinib, stem cell transplant, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Chiwata, Masahiko; Itonaga, Hidehiro; Sato, Shinya; Hashimoto, Miki; Fujioka, Machiko; Kasai, Sachie; Sakamoto, Hikaru; Toriyama, Eo; Nakashima, Jun; Kamijo, Rena; Kitanosono, Hideaki; Kobayashi, Yuji; Horai, Makiko; Taguchi, Masataka; Matsuo, Masatoshi; Makiyama, Junya; Takasaki, Yumi; Matsuo, Emi; Horio, Kensuke; Ando, Koji; Sawayama, Yasushi; Taguchi, Jun; Kawaguchi, Yasuhisa; Tsushima, Hideki; Imanishi, Daisuke; Imaizumi, Yoshitaka; Yoshida, Shinichiro; Jo, Tatsuro; Nonaka, Hiroaki; Moriuchi, Yukiyoshi; Nagai, Kazuhiro; Yokota, Ken-ichi; Hata, Tomoko; Miyazaki, Yasushi published an article in 2021, the title of the article was Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: a report from the Nagasaki CML study group.Category: piperazines And the article contains the following content:

The standard treatment for chronic myeloid leukemia (CML) is the continuous use of tyrosine kinase inhibitors (TKIs), which results in a favorable prognosis for the majority of patients. Recent studies have identified cardiovascular diseases (CVDs) as late adverse events (AEs) related to TKIs. In this study, we evaluated the long-term efficacy and AEs of TKIs, focusing on CVDs. We performed a retrospective survey of CML patients (diagnosed from 2001 to 2016) treated with TKIs in Nagasaki Prefecture. Clin. data were obtained from their medical records. We analyzed the survival, estimated cumulative incidence of CVDs, and risk factors for CVD among CML patients treated with TKIs. The overall survival rate of 264 CML patients treated with TKIs (median age 58 years old) was 89.6% [95% confidence interval (CI), 84.9-92.9%], and 80.5% (95% CI, 73.4-85.9%) at 5 and 10 years after the CML diagnosis, resp. CVD events occurred in 26 patients (9.8%, median age 67.5 years old) with a median 65.5 mo of TKI treatment. The cumulative incidences at 2 and 5 years was 2.4% (95% CI, 1.0-4.8%) and 5.2% (95% CI, 2.8-8.6%), resp. Hypertension and a high SCORE chart risk at the diagnosis of CML were associated with CVD events during TKI treatment. TKI treatment contributed to the long-term survival of CML patients in Nagasaki Prefecture in a “real-world” setting, but the incidence of CVDs seemed to be increased in these patients. A proper approach to managing risk factors for CVD is warranted to reduce CVD events during TKI treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to cardiovascular adverse event tki treatment efficacy chronic myeloid leukemia, adverse event, cardiovascular disease, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2022, Shimazu, Yutaka; Murata, Makoto; Kondo, Takeshi; Minami, Yosuke; Tachibana, Takayoshi; Doki, Noriko; Uchida, Naoyuki; Ozawa, Yukiyasu; Yano, Shingo; Fukuda, Takahiro; Kato, Jun; Ara, Takahide; Eto, Testuya; Ishikawa, Jun; Nakamae, Hirohisa; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko; the working group of the Japan Society for Transplantation and Cellular Therapy published an article.Product Details of 380843-75-4 The title of the article was The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. And the article contained the following:

The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16-75) who underwent their first allo-SCT between Jan. 2001 and Dec. 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-yr OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), resp. (p = 0.017). Multivariate anal. confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup anal. showed poor prognoses for patients who could not obtain a mol. response before allo-SCT and patients with pos. T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4

The Article related to tyrosine kinase inhibitor allogenic stem cell transplantation myeloid leukemia, allogeneic stem cell transplantation, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Product Details of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 30, 2011, He, Zhanwei; Liu, Guoguang; Liu, Haijin; Zhang, Nan; Wang, Gang published an article.Application of 86393-32-0 The title of the article was The effect of different nitrogen forms on the photo-degradation of ciprofloxacin in water. And the article contained the following:

This paper investigated the photo-degradation performance of Ciprofloxacin (CFX) under simulated solar irradiation and the effect of inorganic nitrogen in water. The results showed that the photo-degradation rate was decreased with the increase of initial concentration of CFX and dissolved oxygen. Nitrate accelerated the photo-degradation rate whereas nitrite inhibited it, and ammonium had few effects on it. Along with the increase of pE value, nitrogen form was changed from NH4+ to NO2- or NO3-, the photo-degradation rate of CFX was decreased at the beginning and increased afterwards. The experiments showed that there was no interaction between NH4+ and NO3-. When NO3- and NO2- coexisted, the photo-degradation rate of CFX was lower than the theoretic rate, which indicated that the facilitation of NO3- was inhibited because of the existence of NO2-. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to effect nitrogen form photodegradation ciprofloxacin in water, Waste Treatment and Disposal: Chemical Treatment Of Aqueous Wastes and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics